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Letters to the Editor
RENAL FUNCTION AND ELECTROLYTE DISTURBANCES IN
NORMOCALCAEMIC AND HYPERCALCAEMIC PATIENTS
TREATED WITH MITHRAMYCIN
Several authors have drawn attention
to the side-effects arising after intravenous
infusion of Mithramycin. Gastrointestinal
complaints are the most frequent. Several
workers (Baum, 1968; Brown and Kennedy,
1965; Kennedy, 1970; Ream et al., 1968)
have also noted the possibility of renal
intolerance. To our knowledge no precise
study of renal function has been carried out
in the course of the administration of
Mithramycin.
Seven men and 10 women suffering from
malignant disease, 8 of them having hyper-
calcaemia, were treated with an intravenous
perfusion of Mithramycin. A study of the
renal function was carried out. A loading
dose of Inulin and P.A.H. was given at
time to, The serum concentrations of Inulin
and P.A.H. were kept constant by main-
tenance infusion at a constant rate of
2 ml/min. This infusion continued through-
out the 270 min of the investigation. In the
first period or control period, two specimens
ofurine were collected (ul and u2) correspond-
ing to successive 10 min periods and two
samples of blood (b1 and b2) were taken at
the middle of each urine collection period.
The Mithramycin infusion diluted in 500
dextrose solution was then started at a
rate of 25 jig/kg over 3 hours. Three
specimens of urine were taken, each corres-
ponding to a period of 1 hour (U3, U4 and
u5). Three blood samples w%vere also taken
(b3, b4 a-id b5). After stopping the Mithra-
mycin infusion, two specimens of urine
(u6 and U7) were taken, after two successive
intervals of 20 min and two blood samples
were also taken (b6 and b7).
The following results were recorded:
1. The intravenous infusion of 25 jzg/kg
of Mithramycin at a constant rate over
3 hours is well tolerated. The only abnormal
manifestation was the development in one
patient of a moderate degree of oedema of
the eyelids 30 min after the beginning of the
infusion, but this did not necessitate arrest
of the treatment.
2. Our results demonstrate the absence
of any change in glomerular filtration or
P.A.H. clearance following a short infusion
of Mithramycin.
3. We observed no plasma concentration
variations of sodium, chloride, magnesium
and phosphorus throughout the infusion
of Mithramycin but plasma potassium was
reduced in our 17 patients (4.08 ± 0-42
before and 3-53 ± 0-27 after Mithramycin).
This variation in plasma levels was not
accompanied by an increase of the urinary
output of potassium. Hypokalaemia was
also reported by Baum (1968) and by Ryan,
Schwartz and Northrop (1970) but no
systematic study of the variations in plasma
potassium had been undertaken in their
patients.
4. The serum calcium level falls con-
stantly during the intravenous infusion of
Mithramycin. The fall in serum calcium
varies in degree, is transient and often
insufficient to rectify any marked hyper-
calcaemia. The maximal change seen in
our hypercalcaemic patients was 2-0 mg%0
and in patients with normal serum calcium
the maximal change was 0-6 mg%0. This
fall in serum calcium is never associated
with an increase of the urinary calcium
excretion. An increase of the urinary phos-
phate excretion was noted at the end of the
perfusion. A secondary secretion of para-
thormone could explain the increased phos-
phaturia and the limited action of the
Mithramycin.
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METASTATIC KIDNEY CANCER TREATED WITH MULTIPLE DRUG
THERAPY AT THE ROTTERDAM RADIOTHERAPY INSTITUTE
Sir,-Price and Goldie (1971) reported
promising preliminary results of multiple
drug therapy in the treatment of metastatic
solid cancer. Based on these data it was
decided to assess the possibilities of a slightly
modified form of treatment in patients with
metastatic kidney cancer.
Between 1971 and 1973 18 patients were
submitted to multiple drug chemotherapy
(Table). All patients had proven adeno-
carcinoma of the kidney. The histological
diagnosis wasmade either onthenephrectomy
TABLE.-Rotterdam Radiotherapy Institute
Multiple Drug Therapy
At 0 h
Cyclophosphamide 700 mg/M2, max. 1 g i.v.
5-fluorouracil 500 mg/M2, max. 1 g i.v.
Vincristine 1 mg/M2, max. 2 mg i.v.
Methotrexate 25 mg/M2, in a 6 hours infu-
infusion sion, 4 times. Total
max. 200 mg.
At 24 h
120 mg folinic acid i.v.
At 30 h
15 mg folinic acid i.m., 5 times, at 6 h intervals
Repeated every 4 weeks.
specimen or on a biopsy taken from a
metastasis. All patients had multiple skele-
tal-and/or lymph node-and/or soft tissue-
and/or visceral metastases. All patients
had measurable signs of progressive growth
of their malignancy.
Pulmonary metastases were not con-
sidered to be reliable for assessing progress
of metastases as in a previous study it
became evident that these metastases have
a tendency towards unpredictable spon-
taneous fluctuation and regression (Werf-
Messing and Gilse, 1971).
Painful or "dangerous" lesions, for
instance metastases with risk of fracture,
cord compression, inferior vena cava obstruc-
tion, etc, were treated by radiotherapy.
Eighteenpatients (4females and 14 males)
selected according to the above mentioned
criteria, received multiple drug therapy.
The majority of patients had previously
been treated unsuccessfully with megestrol
acetate, 60 mg daily. The average age of
the patients was 61 years.
Because of serious complications, pro-
gressive metastases or death in spite of
chemotherapy, only one course was given
in 2 cases. For the same reasons treatment
was not repeated after two courses in 5
cases; 11 patients received three or more
courses ofmultiple drug therapy.
In no case could objective response to
chemotherapy be detected. Slight subjective
improvement was observed in one patient.
In another case it was doubtful whether
subjective improvement was real or just the
improvement after recovery from side-effects
of chemotherapy.
As a rule the complications of this
treatment were not severe: severe nausea
(6 cases), severe thrombopenia (1 case),
loss of hair (2 cases, of which one in com-
bination with severe nausea), cardiac failure
(1 case), ulceration of buccal mucosa (3
cases), sepsis (1 case), candida infection
(1 case).
Though the report of Price and Goldie
was encouraging, kidney cancer patients
at the Rotterdam Radiotherapy Institute
had no demonstrable objective benefit by
multiple drug therapy. The complication
rate would have been acceptable had the
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